Creative Medical Technology Holdings is a clinical-stage biotech company developing stem cell and immune cell-based regenerative therapies. Its two most advanced programs are CELZ-201 ADAPT, a cell therapy for chronic lower back pain caused by degenerative disc disease, and CELZ-201 CREATE-1, a cell therapy for newly diagnosed Type 1 diabetes — both currently in Phase I/II trials. Both programs use the company's AlloStem cell line, derived from human perinatal tissue, which does not require patients to take immunosuppressants. Beyond these lead programs, Creative Medical Technology is developing ImmCelz, a personalized therapy that extracts and reprograms a patient's own immune cells before reinfusion, and iPSCelz, an iPSC-based program targeting diabetes developed in partnership with Greenstone Biosciences. The company also has earlier-stage programs in premature ovarian failure, infertility, Parkinson's disease, and organ failure. Creative Medical Technology generates minimal revenue today — earlier commercial products targeting erectile dysfunction and female sexual function have been paused — and funds operations through equity financings. With only four full-time employees, the company operates as a lean R&D organization, relying on CROs and academic partners for trial execution. If therapies are approved, the company's likely revenue model involves licensing platforms to larger pharma companies, royalty income from its patent portfolio, or direct commercialization through physician networks.